Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00047281 · ClinicalTrials.gov registry record · Phase 2
Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00047281 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute.
The verdict
NCT00047281, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Thalidomide and celecoxib may stop the growth of tumor cells by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining thalidomide and celecoxib with etoposide and cyclophosphamide may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining thalidomide and celecoxib with etoposide and cyclophosphamide in treating patients who have relapsed or refractory malignant glioma.
Interventions
- DRUG cyclophosphamide
- DRUG etoposide
- DRUG thalidomide
- DRUG celecoxib
Trial Details
| Field | Value |
|---|---|
| Start Date | 2004-03 |
| Est. Completion | 2006-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00047281
The ClinicalTrials.gov registry entry for NCT00047281 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which cyclophosphamide is the first listed.
NCT00047281 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00047281 about?
NCT00047281 is a clinical study titled "Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma". RATIONALE: Thalidomide and celecoxib may stop the growth of tumor cells by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining thalidomide and celecoxib with etoposide and cyclophosphamide may kill m...
What is the current status of trial NCT00047281?
This trial is currently completed. It is a Phase 2 study. The study started on 2004-03. Estimated completion is 2006-02.
What interventions are being tested in trial NCT00047281?
The interventions under investigation include: cyclophosphamide (DRUG), etoposide (DRUG), thalidomide (DRUG), celecoxib (DRUG).
Who is sponsoring clinical trial NCT00047281?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.